# Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas

> **NCT05991973** · PHASE2 · COMPLETED · sponsor: **Zhejiang University** · enrollment: 44 (actual)

## Conditions studied

- T Lymphoblastic Leukemia/Lymphoma

## Interventions

- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT05991973
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-15
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05991973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05991973, "Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05991973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*